Abstract
A shared pathophysiological abnormality in autism spectrum disorders (ASDs) may be diminished central inhibitory tone, which disrupts a delicate balance between excitation and inhibition. Cholinergic projections from the basal forebrain and other areas provide modulatory influences on central inhibitory tone, and efficient transduction of the acetylcholine (ACh) signal is necessary for maintenance of the balance between excitation and inhibition. This chapter reviews evidence for abnormalities of cholinergic neurotransmission in ASDs and develops the pharmacological rationale for selectively targeting nicotinic acetylcholine receptors (nAChR), especially those containing α7 subunits, as a possible therapeutic intervention. The development of positive allosteric modulators (PAMs) of nAChR makes this a particularly attractive approach as PAMs lack intrinsic activity and are only active where and when ACh is released in the brain to increase the magnitude of its effect. Additionally, specific PAMs may oppose agonist-induced desensitization, which lend themselves to therapies in which they are combined with agonists; combination strategies may have special value when there is diminished density of functional receptors. Also, there are endogenous modulators of cholinergic neurotransmission (e.g., kynurenic acid), whose levels may be modulated to achieve therapeutic goals.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adler LE, Hoffer LJ, Griffith J, et al. Normalization by nicotine of deficit auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry. 1992;32:607–16.
Adler LE, Hoffer LD, Wiser A, et al. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993;150:1856–61.
Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther. 1997;280:1117–36.
Albuquerque EX, Pereira EFR, Braga MFM, et al. Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of α7 receptors. J Physiol (Paris). 1998;92:309–16.
Alkondon M, Pereira EFR, Cortes WS, et al. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in the rat brain neurons. Eur J Neurosci. 1997;9:2734–42.
Bauman ML, Kemper TL. Neuro-anatomic observations of the brain in autism. In: Bauman ML, Kemper TL, editors. The neurobiology of autism. 2nd ed. Baltimore: Johns Hopkins University Press; 1994. p. 119–45.
Ben-Shachar S, Lanpher B, German JR, et al. Microdeletion 15q13.3: a locus with incomplete penetrance for autism, mental retardation, and psychiatric disorders. J Med Genet. 2009;46(6):382–8.
Chez MG, Buchanan TM, Becker M, et al. Donepezil hydrochloride: a double-blind study in autistic children. J Pediatr Neurol. 2003;1(2):83–8.
Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol. 2004;19:165–9.
Cubells JF, DePreo EH, Harvey PD, et al. Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 Deletion syndrome. Am J Med Genet A. 2011;155:805–10.
Cusco I, Medrano A, Gener B, et al. Autism-specific copy number variants further implicate the phosphatidylinositol signaling pathway and the glutamatergic synapse in the etiology of the disorder. Hum Mol Genet. 2009;18(10):1795–804.
Dani JA, Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol. 2007;47:699–729.
Deutsch SI, Rosse RB, Mastropaolo J, et al. Progressive worsening of adaptive functions in down syndrome may be mediated by the complexing of soluble Aβ peptides with the α7 nicotinic acetylcholine receptor: therapeutic implications. Clin Neuropharmacol. 2003;26(5):277–83.
Deutsch SI, Rosse RB, Schwartz BL, et al. Therapeutic implications of selective alpha7 nicotinic receptor abnormality in schizophrenia. Israel J Psychiatry. 2005;42(1):33–44.
Deutsch SI, Urbano MR, Neumann SA, et al. Cholinergic abnormalities in autism: is there a rationale for selective nicotinic agonist interventions? Clin Neuropharmacol. 2010;33(3):114–20.
Deutsch SI, Urbano MR, Burket JA, et al. Pharmacotherapeutic implications of the association between genomic instability at chromosomes 15q13.3 and autism spectrum disorders. Clin Neuropharmacol. 2011;34(6):203–5.
Handen BL, Johnson CR, McAuliffe-Bellin S, et al. Safety and efficacy of donepezil in children and adolescents with autism: neuropsychological measures. J Child Adolesc Psychopharmacol. 2011;21(1):43–50.
Hardan AY, Handen BL. A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol. 2002;12(3):237–41.
Jones CK, Byun N, Bubser M. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacol Rev. 2012;37(1):16–42.
Kemner C, Oranje B, Verbaten MN, et al. Normal P50 gating in children with autism. J Clin Psychiatry. 2002;63:214–7.
Lee M, Martin-Ruiz C, Graham A, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain. 2002;125:1483–95.
Lightfoot AP, Kew JNC, Skidmore J. α7 Nicotinic acetylcholine receptor agonists and positive allosteric modulators. Prog Med Chem. 2008;46:131–71.
Liu Q-S, Kawai H, Berg DK. Β-amyloid peptide blocks the response of α7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA. 2001;98:4734–9.
Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659–85.
Martin-Ruiz CM, Lee M, Perry RH, et al. Molecular analysis of nicotinic receptor expression in autism. Mol Brain Res. 2004;123:81–90.
Mike A, Casstro NG, Albuquerque EX. Choline and acetylcholine have similar kinetic properties of activation and desensitization on the α7 nicotinic receptors in rat hippocampal neurons. Brain Res. 2000;882:155–68.
Ni L, Acevedo G, Muralidharan B, Padala N, et al. Toll-like receptor ligands and CD154 stimulate microglia to produce a factor(s) that promotes excess cholinergic differentiation in the developing rat basal forebrain: implications for neurodevelopmental disorders. Pediatr Res. 2007;61:15–20.
Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16(5):621–9.
Niederhofer H. Treating autism pharmacologically: also tacrine might improve symptomatology in some cases. J Child Neurol. 2007;22(8):1054.
Niederhofer H, Staffen W, Mair A. Galantamine may be effective in treating autistic disorder. BMJ. 2002;325:1422.
Orekhova EV, Stroganova TA, Prokofyev AO, et al. Sensory gating in young children with autism: relation to age, IQ, and EEG gamma oscillations. Neurosci Lett. 2008;434:218–23.
Perry EK, Lee MLW, Martin-Ruiz CM, et al. Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. 2001;158:1058–66.
Perry W, Minassian A, Lopez B, et al. Sensorimotor gating deficits in adults with autism. Biol Psychiatry. 2007;61:482–6.
Rakic O, Arellano JI, Breunig J. Development of the primate cerebral cortex. In: Gazzaniga MS, editor. The cognitive neurosciences. 4th ed. Cambridge: The MIT Press; 2009. p. 7–28.
Rubenstein JLR, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2:255–67.
Sharp AJ, Mefford HC, Li K, Baker C, et al. A recurrent 15q13.3 microdeletion syndrome associated with mental retardation and seizures. Nat Genet. 2008;40(3):322–8.
Shinawi M, Schaaf CP, Bhatt SS, et al. A small recurrent deletion within 15q13.3 is associated with a range of neurodevelopmental phenotypes. Nat Genet. 2009;41(12):1269–71.
Simosky JK, Stevens KE, Kem WR, et al. Intragastric DMXB-a, an α7 nicotinic agonist, improves deficient sensory inhibition in DBA/2 mice. Biol Psychiatry. 2001;50:493–500.
Stevens KE, Kem WR, Mahnir VM, et al. Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology. 1998;136:320–7.
Wang HY, Lee DHS, D’Andrea MR, et al. β-Amyloid1-42 binds to α7 nicotinic acetylcholine receptor with high affinity. J Biol Chem. 2000;275:5626–32.
Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer’s disease and in Down’s syndrome. Ann Neurol. 1985;17:278–82.
Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr Bull. 2010;36(2):211–8.
Wu H-Q, Pereira EFR, Bruno JP, et al. The astrocyte-derived α7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci. 2010;40:204–10.
Yasui DH, Scoles HA, Horike S-I, et al. 15q11.2–13.3 Chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain. Human Mil Genet. 2011;20(22):4311–23.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this entry
Cite this entry
Deutsch, S.I., Schwartz, B.L., Urbano, M.R., Burket, J.A., Benson, A.D., Herndon, A.L. (2014). Nicotinic Acetylcholine Receptors in Autism Spectrum Disorders: Therapeutic Implications. In: Patel, V., Preedy, V., Martin, C. (eds) Comprehensive Guide to Autism. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4788-7_37
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4788-7_37
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4787-0
Online ISBN: 978-1-4614-4788-7
eBook Packages: Behavioral Science